TRI-IMMUNOL LIQ IM 5 LF / 0.5 ML
TETANUS TOXOID : 5 LF / 0.5 ML DIPHTHERIA TOXOID : 12.5 LF / 0.5 ML PERTUSSIS VACCINE : 4 UNIT / 0.5 ML · DIN 02019981 · LEDERLE LABS, DIVISION OF AMERICAN CYANAMID CO
Health Canada status: CANCELLED POST MARKET
What is TRI-IMMUNOL LIQ IM?
TRI-IMMUNOL LIQ IM 5 LF / 0.5 ML contains TETANUS TOXOID : 5 LF / 0.5 ML DIPHTHERIA TOXOID : 12.5 LF / 0.5 ML PERTUSSIS VACCINE : 4 UNIT / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02019981, held by LEDERLE LABS, DIVISION OF AMERICAN CYANAMID CO, supplied as LIQUID for INTRAMUSCULAR administration. Health Canada currently lists it as cancelled post market, status dated 05-Jun-2001. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02019981 |
|---|---|
| Brand name | TRI-IMMUNOL LIQ IM |
| Generic / active ingredient | TETANUS TOXOID : 5 LF / 0.5 ML DIPHTHERIA TOXOID : 12.5 LF / 0.5 ML PERTUSSIS VACCINE : 4 UNIT / 0.5 ML |
| Manufacturer | LEDERLE LABS, DIVISION OF AMERICAN CYANAMID CO |
| Strength | 5 LF / 0.5 ML |
| Dosage form | LIQUID |
| Route of administration | INTRAMUSCULAR |
| Schedule | Schedule D |
| ATC code | J07AJ52 PERTUSSIS, PURIFIED ANTIGEN, COMB. WITH TOXOIDS |
| AHFS class | 80:08.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 05-Jun-2001 |
| Original market date | 1993-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code J07AJ52 PERTUSSIS, PURIFIED ANTIGEN, COMB. WITH TOXOIDS. 1 of 4 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ADACEL | 2.5 MCG / 0.5 ML | SUSPENSION | SANOFI PASTEUR LIMITED | MARKETED | DIN 02240255 |
| TRIPACEL | 3 MCG / 0.5 ML | SUSPENSION | SANOFI PASTEUR LIMITED | APPROVED | DIN 02230273 |
| TRIPACEL HYBRID | 3 MCG / 0.5 ML | SUSPENSION | SANOFI PASTEUR LIMITED | CANCELLED POST MARKET | DIN 02224143 |
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.